$12.35
1.12% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US3968791083
Symbol
GLSI

Greenwich LifeSciences Inc Stock price

$12.35
+1.54 14.25% 1M
+0.38 3.17% 6M
+1.12 9.97% YTD
-1.03 7.70% 1Y
+2.75 28.65% 3Y
+6.60 114.78% 5Y
+6.60 114.78% 10Y
+6.60 114.78% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.14 1.12%
ISIN
US3968791083
Symbol
GLSI
Industry

Key metrics

Basic
Market capitalization
$167.0m
Enterprise Value
$164.2m
Net debt
positive
Cash
$2.8m
Shares outstanding
13.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
127.5
Financial Health
Equity Ratio
61.9%
Return on Equity
-623.1%
ROCE
-1,279.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-16.8m | -
EBIT
$-16.8m | $-13.1m
Net Income
$-16.6m | $-12.7m
Free Cash Flow
$-7.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-74.1% | -
EBIT
-74.1% | 18.5%
Net Income
-79.3% | 19.9%
Free Cash Flow
-9.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.3
FCF per Share
$-0.6
Short interest
15.7%
Employees
6
Rev per Employee
$0.0
Show more

Is Greenwich LifeSciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Greenwich LifeSciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Greenwich LifeSciences Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Greenwich LifeSciences Inc forecast:

Buy
86%
Hold
14%

Financial data from Greenwich LifeSciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.40 3.40
118% 118%
-
- Research and Development Expense 13 13
66% 66%
-
-17 -17
74% 74%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -17 -17
74% 74%
-
Net Profit -17 -17
79% 79%
-

In millions USD.

Don't miss a Thing! We will send you all news about Greenwich LifeSciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Greenwich LifeSciences Inc Stock News

Neutral
GlobeNewsWire
one day ago
STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events.
Neutral
GlobeNewsWire
4 months ago
STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date & Future Plans...
Neutral
GlobeNewsWire
4 months ago
STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label immune response data.
More Greenwich LifeSciences Inc News

Company Profile

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Head office United States
CEO Snehal Patel
Employees 6
Founded 2006
Website greenwichlifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today